BJDX — Bluejay Diagnostics, Inc.

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1704287 ·
Last close
$2.15
Market Cap
$2.41M
52W High
$28.00
52W Low
$1.84
ADV30
46,296
Next earnings
—
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Jun 2026 0 — -2,349,124 -2,324,013 11,533,900 9,598,916 2,119,060
Mar 2026 0 — -1,938,831 -1,919,241 5,598,603 3,684,457 1,417,408
Dec 2025 0 — -1,461,747 -1,429,812 7,119,237 5,164,875 1,143,948
Sep 2025 0 — -1,616,947 -1,597,632 4,890,258 3,082,268 1,197,476

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,903,219
Investing CF
$-331,822
Financing CF
$11,390,881
CapEx
$-161,762
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-12.75
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-45,760,521
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-7,315,012
Pretax Income TTM
$-7,270,698
Interest Exp TTM
$609
Analysts
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -6,952,972 -6,848,483 7,120,000 1,140,000 5,975,289 -6,053,575
Dec 2024 0 -7,169,616 -7,717,794 6,660,000 927,924 5,729,499 -7,820,822
Dec 2023 0 -10,311,217 -9,953,888 4,870,000 1,973,683 2,894,848 -8,313,870
Dec 2022 249,040 -9,317,776 -9,296,948 13,500,000 1,979,992 11,541,273 -7,741,593
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$94,192
NetIncome TTM
$-7,270,698
OpCashFlow TTM
—
Assets (Latest)
$11,533,900
Forward EPS
$-0.32

Peers — same industry

TickerNameMarket CapLastDaily %
DROR Dror Ortho-Design, Inc. $2.44M $0.00 —
NUWE Nuwellis, Inc. $2.22M $4.10 —
AMIX Autonomix Medical, Inc. $2.21M $1.08 —
CODX Co-Diagnostics, Inc. $2.06M $0.20 —
ICCM IceCure Medical Ltd. $2.84M $0.83 —

News headlines (Yahoo Finance, 1h cache)

Bluejay Diagnostics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 21:30 · Yahoo
Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
2026-10-30 15:30 · Yahoo
Bluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization Readiness
2026-10-13 10:30 · Yahoo
Bluejay Diagnostics Advances Rapid Biomarker Testing For Sepsis Patients
2026-10-06 13:05 · Yahoo
Bluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic Shock
2026-10-06 10:30 · Yahoo
Bluejay Diagnostics Federal Healthcare Partnership Builds Commercial Pathway Ahead of FDA Clearance
2026-09-08 14:55 · Yahoo
Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and Commercialization
2026-08-13 10:00 · Yahoo
Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study
2026-07-21 10:30 · Yahoo
Bluejay Diagnostics Provides First Quarter 2026 Corporate Update
2026-05-07 20:01 · Yahoo
Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership
2026-06-02 10:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.